Quality of life improves after any of several uterine-fibroid treatments

Share this content:

A study comparing health-related quality-of-life measures among three different interventions for uterine fibroids showed quality of life to increase subsequent to each treatment: abdominal hysterectomy, noninvasive magnetic resonance-imaging-guided focused ultrasound surgery (MRgFUS), and minimally invasive uterine artery embolization (UAE). 

Fiona M. Fennesssy, MD, PhD, an assistant professor of radiology at Harvard Medical School, led a survey of 74 women who underwent UAE (mean age: 44 years), 62 who underwent hysterectomy (mean age: 47 years), and 61 who underwent MRgFUS (mean age: 47 years) for symptomatic uterine fibroids between 2004 and 2006. The researchers were able to compare pretreatment and posttreatment quality-of-life measures by obtaining for each intervention a utility weight—a single unit of measure that encompasses all the quality-of-life benefits of a particular health care option.

“Quality of life significantly increased following each of the fibroid treatment options,” noted Dr. Fennessy in a statement describing the survey results, which were published online ahead of print by the journal Radiology. “But patients rated the non- or minimally invasive treatments—UAE and MRgFUS—more favorably.”

The investigators also used the waiting trade-off (WTO) method to compare short-term utility weights for actual treatments. The WTO method is based on the fact that people wait longer to avid noxious tests and/or procedures.

The median WTO wait time was highest for hysterectomy (21.6 weeks), meaning that hysterectomy patients said they would wait 21 weeks in order to avoid the procedure.  The UAE and MRgFUS patients each said that they would put off their procedures by a median of only 14.1 weeks.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs